IsoRay teams up with Russia firm to open routes for prostate cancer tech
This article was originally published in Clinica
Executive Summary
IsoRay Medical, developer of the Proxcelan Cesium-131 brachytherapy seeds, is set to capitalise on the opportunities in the fast-growing East European healthcare market, after having bought a 30% ownership in a newly-formed Russian medical isotope manufacturer UralDial.